What is the 13F Pro Quality Score for OM?

13F Pro ranks Outset Medical, Inc. (OM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OM's current score at https://13fpro.ai/research/OM (free sign-up required for the full ranking).

Which hedge funds own the most OM stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of OM include FMR, BML Capital Management,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/OM as soon as new 13F filings post.

Where does 13F Pro source OM data?

All Outset Medical, Inc. fundamentals and ownership data come directly from SEC EDGAR. Outset Medical, Inc. files with the SEC under CIK 1484612. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OM in?

Outset Medical, Inc. (OM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OM research updated on 13F Pro?

OM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Outset Medical, Inc.(OM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1484612 OM stock profile & AI dashboard →

13F Pro Quality Score

17.6/100

Rank #2,717 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

21.6/100

Profitability

9.5/100

Balance Sheet

7.3/100

Earnings Quality

30.0/100

Free Cash Flow

10.0/100

Institutional Flow

74.4/100

Revenue Scale

19.2/100

Dilution Risk

14.0/100

OM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Outset Medical, Inc. (OM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OM at 17.6/100 on a 32-signal composite quality model, placing it at rank #2,717 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (7.3) and profitability (9.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Outset Medical, Inc. reports quarterly revenue of $27.9M, net income of $-19.0M, an operating margin of -60.7%. Top institutional holders of OM by reported 13-F value include FMR, BML Capital Management,, BlackRock,, based on the most recent SEC filings. OM trades on the Nasdaq exchange and files with the SEC under CIK 1484612. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Outset Medical, Inc. directly from SEC EDGAR. Outset Medical, Inc.'s 13F Pro composite quality score has ranged between 13 and 34 since 2021, currently 17.6 — a declining long-term trajectory across 28 quarterly and live scoring snapshots.

Revenue

Q1 2026

$27.9M

Net Income

Q1 2026

$-19.0M

Free Cash Flow

Q1 2026

$-12.9M

Operating Margin

Q1 2026

-60.7%

D/E Ratio

Q1 2026

0.87

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+5.1% YoY

$119.5MFY 2025

FY22 $115.4MFY23 $130.4MFY24 $113.7MFY25 $119.5M

Net Income

+36.2% YoY

$-81.7MFY 2025

FY22 $-163.0MFY23 $-172.8MFY24 $-128.0MFY25 $-81.7M

Operating Income

+41.2% YoY

$-66.7MFY 2025

FY22 $-161.0MFY23 $-169.8MFY24 $-113.4MFY25 $-66.7M

EPS (Diluted)

+85.5% YoY

$-5.37FY 2025

FY22 $-3.38FY23 $-52.28FY24 $-36.96FY25 $-5.37

Total Assets

-4.1% YoY

$264.5MFY 2025

FY22 $400.1MFY23 $313.8MFY24 $275.8MFY25 $264.5M

Total Debt

-51.2% YoY

$96.2MFY 2025

FY22 $101.1MFY23 $130.1MFY24 $197.4MFY25 $96.2M

Op. Cash Flow

+60.2% YoY

$-46.3MFY 2025

FY22 $-145.7MFY23 $-131.4MFY24 $-116.3MFY25 $-46.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$119.5M +5.1%	$113.7M -12.8%	$130.4M +13.0%	$115.4M +12.4%	$102.6M +580.5%	$15.1M
Net Income	$-81.7M +36.2%	$-128.0M +25.9%	$-172.8M -6.0%	$-163.0M -23.5%	$-131.9M -93.2%	$-68.3M
Operating Income	$-66.7M +41.2%	$-113.4M +33.2%	$-169.8M -5.4%	$-161.0M -23.4%	$-130.5M -85.6%	$-70.3M
EPS (Diluted)	$-5.37 +85.5%	$-36.96 +29.3%	$-52.28 -1446.7%	$-3.38 -17.0%	$-2.89	—
Total Assets	$264.5M -4.1%	$275.8M -12.1%	$313.8M -21.6%	$400.1M -13.7%	$463.5M +424.5%	$88.4M
Total Debt	$96.2M -51.2%	$197.4M +51.7%	$130.1M +28.7%	$101.1M +218.0%	$31.8M -13.1%	$36.6M
Operating Cash Flow	$-46.3M +60.2%	$-116.3M +11.5%	$-131.4M +9.9%	$-145.7M -11.9%	$-130.3M -85.3%	$-70.3M

AI Insight: OM Financial Trends

Outset Medical shows modest operating leverage improvements but revenue has stalled around $29-31M with persistent quarterly losses of $18-19M.

• Operating income improved from -$31M in Q2 2024 to -$16M in Q1 2026, showing gradual margin expansion.

• Revenue growth stagnated, declining from $31M in Q2 2025 to $28M in Q1 2026.

• Total debt decreased significantly from $197M in Q4 2024 to $97M in Q1 2026.

• Operating cash flow improved from -$33M in Q2 2024 to -$13M in Q1 2026.

⚠ Equity continues declining from $170M in Q1 2025 to $112M in Q1 2026 despite debt reduction.

⚠ Revenue appears to have plateaued with three consecutive quarters below $30M after Q2 2025 peak.

AI Insight: OM Ratio Trends

Outset Medical's operating losses remain severe at -57% margin despite improving from worst levels of -112% in Q2 2024.

• Operating margin improved from -112.3% in Q2 2024 to -53.7% in Q2-Q3 2025 before deteriorating to -60.7% in Q1 2026.

• Debt-to-equity ratio declined dramatically from peak of 7.36 in Q4 2024 to 0.55 in Q1 2025.

• ROA losses moderated from -43.8% in Q2 2024 to -25.7% in Q2-Q3 2025 but worsened to -30.4% in Q1 2026.

⚠ Operating margin deteriorated 730 basis points from Q3 2025 to Q1 2026, reversing previous improvement trend.

⚠ Debt-to-equity increased for three consecutive quarters from 0.55 in Q1 2025 to 0.87 in Q1 2026.

Get alerted when OM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Outset Medical, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OM

FMR LLC
$10.5M2,741,673 sh
BML Capital Management, LLC
$7.3M1,902,201 sh
BlackRock, Inc.
$4.9M1,263,219 sh
BANK OF AMERICA CORP /DE/
$3.6M949,397 sh
PERCEPTIVE ADVISORS LLC
$3.2M833,333 sh
AQR CAPITAL MANAGEMENT LLC
$3.1M808,285 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.9M763,822 sh
PFM Health Sciences, LP
$2.3M594,630 sh
Ensign Peak Advisors, Inc
$2.0M526,585 sh
Assenagon Asset Management S.A.
$1.9M504,093 sh

Fund	Value	Shares
FMR LLC	$10.5M	2,741,673
BML Capital Management, LLC	$7.3M	1,902,201
BlackRock, Inc.	$4.9M	1,263,219
BANK OF AMERICA CORP /DE/	$3.6M	949,397
PERCEPTIVE ADVISORS LLC	$3.2M	833,333
AQR CAPITAL MANAGEMENT LLC	$3.1M	808,285
VANGUARD CAPITAL MANAGEMENT LLC	$2.9M	763,822
PFM Health Sciences, LP	$2.3M	594,630
Ensign Peak Advisors, Inc	$2.0M	526,585
Assenagon Asset Management S.A.	$1.9M	504,093

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OM on your watchlist

Track score changes the day Outset Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OM a good stock to buy?

13F Pro's AI-powered analysis of Outset Medical, Inc. (OM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OM are available on the OM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Outset Medical, Inc.'s investment landscape.